Scynexis plans to cut 40% of staff and license its approved antifungal in pivot to R&D
20th October 2022 Uncategorised 0Scynexis plans to cut 40% of staff and license its approved antifungal in pivot to R&D fkansteiner Thu, 10/20/2022 – 15:54 More: Scynexis plans to cut 40% of staff and license its approved antifungal in pivot to R&D Source: fierce
read more